Efficacy and safety of aumolertinib in EGFR-mutated non-small cell lung cancer with leptomeningeal metastasis: a single‑center retrospective study - Summary - MDSpire
Advertisement
Efficacy and safety of aumolertinib in EGFR-mutated non-small cell lung cancer with leptomeningeal metastasis: a single‑center retrospective study
To assess the efficacy and safety of aumolertinib in patients with EGFR-mutated non-small cell lung cancer (NSCLC) and leptomeningeal metastasis (LM).
Key Findings:
79 patients with EGFR-mutant NSCLC and LM were enrolled.
Median overall survival (OS) and progression-free survival (PFS) were evaluated.
Aumolertinib demonstrated promising efficacy in improving survival outcomes in this patient population.
Interpretation:
Aumolertinib appears to be a viable treatment option for patients with EGFR-mutated NSCLC and LM, potentially improving survival outcomes compared to previous therapies.
Limitations:
Retrospective design may introduce bias.
Limited sample size may affect the generalizability of the findings.
Lack of CSF assessment data for a significant portion of patients.
Conclusion:
Aumolertinib shows potential efficacy and safety in treating EGFR-mutated NSCLC with LM, warranting further investigation in larger, prospective studies.
